研究計畫

科技部

  1. Antibody-based gene therapy for methamphetamine addiction. MOST 104-2320-B-030-011. 2015/11/01~2016/07/31.
  2. Investigate the therapeutic potential of a ubiquitin ligase fused single-chain antibody on the α-synuclein overexpression rat model of Parkinson's disease. MOST 105-2628-B-030-001. 2016/08/01~2017/07/31.
  3. Investigate the therapeutic potential of a bispecific single-chain antibody for the clearance of extracellular alpha-synuclein aggregates in the rat model of Parkinson's disease. MOST 106-231-B-030-005. 2017/08/01~2018/07/31.
  4. Antibody-based gene therapy for methamphetamine addiction (part-2). MOST 107-2314-B-030-009. 2018/08/01~2019/07/31.
  5. Investigate the therapeutic potential of an intracellular antibody against monomeric alpha-synuclein for Prakinson's disease in the rat model selectively overexpressing alpha-synuclein in the dopaminergic neurons. MOST 108-2314-B-030-007. 2019/08/01~2020/07/31.
  6. Targeting monomeric and oligomeric alpha-synuclein by intracerebral delivery of intrabody genes for the treatment of Parkinson's disease. MOST 110-2314-B-030-008. 2021/08/01~2022/07/31.
  7. Investigate the potential of virus-mediated intracerebral expression of an intrabody against alpha-synuclein to prevent Parkinson's disease in normal aging rats. MOST 111-2314-B-030-008. 2022/08/01~2023/07/31.
  8. Target alpha-synuclein by gene-engineered exosomes for the treatment of Parkinson's disease. NSTC 112-2314-B-030-009. 2023/08/01~2024/07/31.

  9. Reduce alpha-synuclein accumulation by genetically engineered human umbilical cord mesenchymal stem cell-derived exosomes for the treatment of Parkinson’s disease. NSTC 113-2314-B-030-006. 2024/08/01~2025/07/31.

 

非科技部

  1. Effects of opioids on the infection and replication of human influenza A virus. 2014/10/20~20145/06/30.
  2. Application of cell-penetrating peptides in the induction of cytotoxic T lymphocytes by protein-based vaccines. 2015/09/01~2016/08/31.
  3. Assess the feasibility of developing a mouse-human chimeric anti-methamphetamine monoclonal antibody into a medication for methamphetamine addiction. 2015/09/15~2016/06/30.
  4. Investigate the therapeutic potential of the combination of Rituximab and a CD16A+ natural killer-like cell line in a mouse xenograft model of B-cell lymphoma. 2016/12/01~2017/11/30.
  5. Evaluate the protective effect of astaxanthin on experimental infection of human influenza A virus. 2017/03/01~2018/02/28.
  6. Assessment of Pro5 pentamers used for the isolation of specific T cell receptors from gene libraries. 2019/08/01~2020/07/31.
  7. Investigate the effect of blood-brain-barrier shuttle peptides on the binding activity of the alpha-synuclein specific antibody. 2020/09/01~2021/08/31.
  8. Evaluate the potential effect of a secreted single-chain antibody against alpha-synucelin accumulation. 2020/11/01~2021/06/30.
  9. Establish a bioluminescence-based cytotoxic assay for determining the cytotoxicity of cytokine-induced immune killer cells. 2021/11/01~2022/10/31.
  10. Investigate the therapeutic potential of mesenchymal stem cells and their exosomes after ischemic stroke in rats.  2023/05/01~2024/04/30.
  11. Establishment of in vitro expansion techniques for large-scale preparation of human umbilical cord mesenchymal stem cells and their secreted exosomes. 2023/06/01~2024/05/31.

  12. Investigate the potential of human umbilical cord mesenchymal stem cell-derived exosomes on skin regeneration. 2024/01/01~2024/12/31.

  13. Optimize the functional assay protocols for the exosomes derived from human umbilical cord mesenchymal stem cells. 2024/10/01~2025/09/30.

  14. Therapeutic potential of human umbilical cord mesenchymal stem cell-derived exosomes in a mouse model of Parkinson’s disease induced by alpha-synuclein overexpression. 2024/10/01~2026/09/30.